Author
@Biomaven Biomaven
grade Ax.com/Biomaven ↗
Named biotech specialist who handicaps drug catalysts via clinical depth and patent law
Posts original, deeply reasoned biotech/pharma analysis — cl
trader score
-0.63
hit rate
50%
mean α
-1.68%
signals 14d
11
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 10 scored bets: 50% hit rate, -1.68% mean alpha, trader score -0.63. Their last-14d mentions, direction-adjusted, have moved -5.3% since posting (mean over 6 mentions with price data).
Recent signals11receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-10-15 | MRNA | @Biomaven | +0.00 | The author attributes biotech weakness to rates, China competition, politics, fund deleveraging and AI beliefs. | -15.4% | tweet ↗ |
| 2026-10-14 | LQDA | @Biomaven | -0.50 | Says off-label LQDA use will be severely restricted, favoring UTHR while LQDA's next-generation drug remains in trials. | +25.7% | tweet ↗ |
| 2026-10-14 | UTHR | @Biomaven | +0.30 | Says off-label LQDA use will be severely restricted, favoring UTHR while LQDA's next-generation drug remains in trials. | +8.8% | tweet ↗ |
| 2026-10-13 | LQDA | @Biomaven | -0.15 | Corrects an earlier bullish claim by narrowing product freedom to PAH. | +59.1% | tweet ↗ |
| 2026-10-13 | LQDA | @Biomaven | +0.65 | Calls the resolution very favorable and expects meaningful off-label prescribing. | +59.1% | tweet ↗ |
| 2026-10-11 | MRK | @Biomaven | -0.60 | Calls MRK's Wnt agonist a failure due to slightly worse efficacy and more adverse events. | -0.2% | tweet ↗ |
| 2026-10-09 | · | @Biomaven | · | Argues short-term investor behavior creates opportunities for long-term investors. | · | tweet ↗ |
| 2026-10-08 | · | @Biomaven | · | Argues biology's combinatorial molecular complexity will be a harder test for advanced computational systems. | · | tweet ↗ |
| 2026-10-08 | · | @Biomaven | · | Finds a mathematical result interesting but says it and faster matrix multiplication lack practical utility so far. | · | tweet ↗ |
| 2026-10-08 | · | @Biomaven | · | Warns that open-weight models are not equivalent to open source and may conceal unknown risks. | · | tweet ↗ |
| 2026-10-05 | · | @Biomaven | · | Criticizes reliance on creatinine-imputed eGFR instead of cystatin C, but names no security. | · | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.